Are there safety concerns with the RSV vaccine for adults over 60?
The RSV vaccine is recommended for adults aged 60 and older in the United States. Reports examining safety findings one year after this recommendation were released to ensure the vaccine is safe for this age group. These reports describe the safety profile observed in the population receiving the vaccine.
What the research says
A report specifically examining safety findings one year after the RSV vaccine was recommended for adults 60 and older found no significant difference in serious adverse events between the vaccine and a placebo 5. This suggests that the vaccine does not introduce new serious risks for older adults compared to receiving no vaccine.
A systematic review and meta-analysis of randomized control trials also evaluated the safety of RSV vaccines in older adults. This study found no significant difference in serious adverse events between RSV vaccines and placebo 9. The review included multiple trials to build a comprehensive picture of the safety profile for this specific age group.
Earlier trials in adults, such as those involving an adenovirus vector vaccine, also reported that solicited adverse events were generally mild to moderate with no serious adverse events reported 10. While these specific trials focused on younger adults (18-50 years), the overall safety profile supports the use of similar vaccine platforms in older populations without raising new safety concerns.
What to ask your doctor
- What are the specific safety findings for the RSV vaccine in adults over 60 based on recent reports?
- How do the serious adverse event rates for the RSV vaccine compare to other vaccines I might receive?
- Are there any specific side effects I should watch for after getting the RSV vaccine?
- Is the RSV vaccine recommended for me based on my current health conditions?
This question is drawn from common patient questions about Infectious Disease and answered using cited medical research. We do not provide individualized advice.